A novel recombinant immunocasp-6 fusion gene specifically and efficiently suppresses HER2-overexpressing osteosarcoma

Area of Science:

• Oncology
• Immunotherapy
• Molecular Biology

Background:

• Osteosarcoma is a common pediatric bone cancer with poor prognosis due to metastasis.
• Current treatments lack efficacy and have significant toxicity.
• Immunotherapy targeting human epidermal growth factor receptor 2 (HER2) shows promise for HER2-overexpressing tumors.

Purpose of the Study:

• To investigate the efficacy of a novel fusion gene, immunocasp-6, for treating HER2-overexpressing osteosarcoma.
• To evaluate immunocasp-6's ability to specifically target and induce apoptosis in cancer cells.
• To assess the therapeutic potential of immunocasp-6 in preclinical models.

Main Methods:

• Constructed immunocasp-6 by fusing a HER2-specific antibody, Pseudomonas exotoxin A, and active caspase-6.
• Tested immunocasp-6's ability to induce apoptosis in HER2-positive osteosarcoma cells in vitro.
• Administered liposome-encapsulated pCMV-immunocasp-6 via intramuscular injection in mice bearing human osteosarcoma.

Main Results:

• Immunocasp-6 specifically recognized and induced apoptosis in HER2-overexpressing osteosarcoma cells in vitro.
• In vivo, immunocasp-6 significantly inhibited tumor growth and prolonged animal survival.
• Treatment with immunocasp-6 effectively prevented tumor metastasis in preclinical models.

Conclusions:

• Immunocasp-6 demonstrates specific recognition and targeted induction of apoptosis in HER2-overexpressing osteosarcoma.
• This novel immunotherapy shows significant potential for inhibiting tumor growth, preventing metastasis, and treating HER2-positive osteosarcoma.
• Immunocasp-6 represents a promising therapeutic strategy for human HER2-overexpressing tumors.